A TLR7/8 agonist–chitosan conjugate as an adjuvant for carbohydrate-based anticancer vaccine development

Abstract

The TLR7/8 agonist imidazoquinoline (IMDQ), 1-(4-(amino-methyl)benzyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-amine, conjugated to chitosan was found to be a superior adjuvant to aluminum salts for vaccination against tumor-associated carbohydrate antigens.

Graphical abstract: A TLR7/8 agonist–chitosan conjugate as an adjuvant for carbohydrate-based anticancer vaccine development

Supplementary files

Article information

Article type
Communication
Submitted
11 Jun 2025
Accepted
15 Aug 2025
First published
20 Aug 2025

Chem. Commun., 2025, Advance Article

A TLR7/8 agonist–chitosan conjugate as an adjuvant for carbohydrate-based anticancer vaccine development

X. Yin, G. Tong, S. Huang, L. Chen, A. Yang, W. Teng, X. Luo and K. Zhu, Chem. Commun., 2025, Advance Article , DOI: 10.1039/D5CC03299G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements